FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma
FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma
复制标题
DOI：
10.3892/or_00000692
复制
发表时间：
2010-03-01
期刊：
影响因子：
4.2
通讯作者：
Kitano, Motoo
中科院分区：
文献类型：
--
作者：
Tanuma, Jun-Ichi;Izumo, Toshiyuki;Kitano, Motoo
成纤维细胞生长因子受体4(FGFR4)基因和TP53突变是头颈部、膀胱癌的预后因素。胸部和结肠。为了确定它们是否适用于口腔鳞状细胞癌(OSCC)，我们研究了150名接受根治性手术的OSCC患者和100名未患癌症的人的OSCC样本中的这两个基因。在OSCC。FGFR4基因Gly388Arg多态和TP53基因突变与否与手术中肿瘤的临床病理特征无明显相关性。然而，研究发现，FGFR4 Arg388等位基因和TP53突变与预后不良密切相关。此外，这两个参数协同影响口腔鳞癌患者的生存。在根治性手术后60个月的观察中，携带纯合子Arg388 FGFR4加突变的TP53的大多数患者死于癌症，而携带纯合子Gly388 FGFR4加野生型TP53的患者中有90%存活。因此，FGFR4 Gly388Arg多态和TP53突变及其组合是预测口腔鳞癌患者预后的良好指标。
The genotype of the fibroblast growth factor receptor 4 (FGFR4) gene and TP53 Mutation have been reported as prognostic factors for cancers of the head and neck, bladder. breast and colon. To determine whether they are applicable for oral squamous Cell carcinoma (OSCC), we investigated these two genes in OSCC samples from 150 patients who had Undergone radical Surgery and in 100 cancer-free individuals. In OSCC. the FGFR4 Gly388Arg polymorphism and the presence or absence of Mutation in TP53 did not show a significant association with the clinicopathological features of the tumors at surgery. However, the FGFR4 Arg388 allele, as Well as Mutations in TP53, was found to be closely associated with poor prognosis. Moreover, these two parameters synergistically affected the survival of OSCC patients. During 60 months of observation after radical surgery, a majority of patients with homozygous Arg388 FGFR4 Plus Mutated TP53 died of cancer, whereas >90% patients carrying homozygous Gly388 FGFR4 plus wild-type TP53 survived. Therefore, the FGFR4 Gly388Arg polymorphism and TP53 Mutations, as well as their combinations, are excellent predictors of the prognosis for OSCC patients.